

## PRESS RELEASE

# Hansa Biopharma participating at H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

Lund, Sweden, 12 March, 2026. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq in New York, from 17:00-17:30 EDT, on Tuesday 19 May, 2026.

If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at [ir@hansabiopharma.com](mailto:ir@hansabiopharma.com).

**Event:** H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq, Hansa Biopharma Fireside Chat

**Date, Time, and Place:** Tuesday 19 May, 17:00-17:30 EDT, Nasdaq World Headquarters, New York

**Speakers:**

- Maria Törnsén, COO and President U.S., Hansa Biopharma
- Douglas Tsao, Senior Research Healthcare Analyst, H.C. Wainwright & Co.

[Webcast Link](#)

--- ENDS ---

**Contacts for more information:**

Evan Ballantyne, Chief Financial Officer  
[IR@hansabiopharma.com](mailto:IR@hansabiopharma.com)

Kerstin Falck, VP Global Corporate Affairs  
[media@hansabiopharma.com](mailto:media@hansabiopharma.com)

**Notes to editors**

**About Hansa Biopharma**

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at [www.hansabiopharma.com](http://www.hansabiopharma.com) and follow us on [LinkedIn](#).

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.